Concepedia

Author

Monica Luchi

Incyte (United States)

Also Known As

M Luchi, M. Luchi, Monica E Luchi, Monica E. Luchi, Monica Luchi

18

Publications

1.2K

Citations

11

H-Index

6

Concepts

All Affiliations

Incyte (United States)Novartis (Switzerland)New England Baptist HospitalEli Lilly (United States)Merck & Co., Inc., Rahway, NJ, USA (United States)
ML

About

Monica Luchi is an author at Incyte (United States) specializing in clinical trials, rheumatology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

15

2

Pharmacology

1

1

15

3

Rheumatology

1

1

15

4

Clinical Trials

1

1

15

5

Pharmacotherapy

1

1

15

Monica Luchi

×

9

Publications

1.1K

Citations

9

H-Index

YearCitations

Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease

Ian R. Reid, Paul D. Miller, Kenneth W. Lyles,

New England Journal of Medicine

2005

429

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Edward Keystone, Peter C. Taylor, Edit Drescher,

Annals of the Rheumatic Diseases

2014

276

Comparison of radiographic joint space width with magnetic resonance imaging cartilage morphometry: Analysis of longitudinal data from the osteoarthritis initiative

J. Duryea, Gesa Neumann, Jingbo Niu,

Arthritis Care & Research

2010

119

Change in cartilage morphometry: a sample of the progression cohort of the Osteoarthritis Initiative

David J. Hunter, Jingbo Niu, Yuqing Zhang,

Annals of the Rheumatic Diseases

2008

114

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

Robert Bissonnette, Monica Luchi, Rosanne Fidelus-Gort,

Journal of Dermatological Treatment

2016

77

Primary idiopathic pulmonary hypertension complicated by pulmonary arterial thrombosis. Association with antiphospholipid antibodies

Monica Luchi, Ronald A. Asherson, Robert G. Lahita

Arthritis & Rheumatism

1992

53

LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis

Ed Keystone, Peter C. Taylor, Mark C. Genovese,

Annals of the Rheumatic Diseases

2012

19

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

M. C. Genovese, Ed Keystone, P. W. J. Taylor,

Oxford University Research Archive (ORA) (University of Oxford)

2012

15

Soluble urate in sera and synovial fluids from patients with different joint disorders.

Beutler Am, Keenan Gf, Scott M. Soloway,

PubMed

1996

11

Page 1